SAB Biotherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $207.36M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2023 Ended Dec 31, 2023 | Mar 29, 2024 | During market hours | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 31, 2023 | After market close | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 22, 2021 | Before market open | – | – | – |
Press releases
Announcements SAB Biotherapeutics filed with the SEC
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Other events · EX-99.1 to Form 8-K
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Presentation Q1 2026 Targeting T1D Modifying Disease Moving Beyond Insulin EXHIBIT 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corporate Presentation January 2026 Modifying Disease Delaying Progression Transforming Treatment Company Logo © 2026 SAB BIOTHERAPEUTICS, INC. Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SAB BIO Announces Oversubscribed $175 Million Private Placement
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
Other events · EX-99.1 to Form 8-K
SAB BIO INNOVATION DAY ACCELERATING DISEASE-MODIFYING TREATMENTS IN AUTOIMMUNITY January 28, 2025 (Nasdaq: SABS) EXHIBIT 99.2
Other events · EX-99.2 to Form 8-K
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics European Association for the Study of Diabetes 60th Annual Meeting INNODIA SYMPOSIUM Madrid, Spain September 9, 2024 © 2024 SAB BIOTHERAPEUTICS, INC. EXHIBIT 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
SAB BIO Appoints Lucy To as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Announces Departure of Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
Other events · EX-99.1 to Form 8-K
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Results of operations · EX-99.1 to Form 8-K
SAB Biotherapeutics Announces Executive Leadership Change
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE OF THE COMPANY, DATED MARCH 31, 2023
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
Regulation FD disclosure · EX-99.1 to Form 8-K
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
Regulation FD disclosure · EX-99.1 to Form 8-K